Eisai Co., Ltd. announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta protofibril* antibody lecanemab in people living with mild cognitive impairment due to Alzheimer’s disease and mild AD using data from the Phase 3 clinical study, Clarity AD by applying a validated disease simulation model.
